There are many effective treatments for MDD and BD, including psychotherapy and pharmacotherapy; however, ECT continues to be one of the most effective biological therapies for patients with severe and (or) treatment-resistant mood disorders. 7 In 1948, the World Health Organization defined health as "a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity." 8 Traditionally, efficacy in RCTs of ECT has been determined on the basis of a change in symptoms on a continuous measure of symptoms, such as the HDRS 9 or the Young Mania Rating Scale, 10 at the end of a course of treatment.
Although obtaining clinical response represents an important therapeutic milestone, it does not necessarily indicate a recovery from mood disorders, since many patients with clinical response will still be left with substantial residual impairment in functioning. Studies have shown that the presence of residual symptoms after an episode of MDD is associated with higher risk of relapse, recurrence, chronicity, suicide, development of cardiovascular disease, and poor QOL. [11] [12] [13] While it is generally assumed that an improvement in depressive symptoms equals an improvement in psychosocial outcome, there is a lack of clinical data available on the psychosocial outcome of patients treated with ECT.
Recent task force and other reports from the American Psychiatric Association, 14 the United Kingdom Royal College of Psychiatrists, 15 and others 16 confirm that ECT is still widely practised in psychiatric hospitals. Despite the common use of ECT, there is comparatively little systematic information on the effectiveness of ECT outside of academic psychiatric institutions. To our knowledge, there are only 2 published reports on the effectiveness of ECT in community settings. 17, 18 Also, there has been little information on long-term outcomes of ECT.
Here we report the results of a retrospective chart review of a large sample of patients treated for MDD and BD (I and II) with ECT at a community hospital. We determined the overall clinical and psychosocial outcomes during short-and long-term (2-year) follow-up.
Methods

Setting and ECT Procedure
All ECT treatments took place at Ridge Meadows Hospital and Health Care Centre, which is an acute and extended care hospital providing primary and secondary level inpatient health care as well as emergency services. It is a community hospital with a catchment population of about 95 000 people. The hospital had a 14-bed psychiatric unit during the time of the study.
ECT procedures were conducted by 4 psychiatrists in a suite within the Ridge Meadows Hospital, with 90% of the treatments conducted by a single specialist. Anaesthesia was induced by sodium thiopental and (or) propofol (2 to 3 mg/kg), and muscle relaxation was achieved by succinylcholine administration (0.5 mg/kg). The staff used the MECTA SR-1 to administer ECT up until January 2001 and the MECTA 5000-Q from January 2001 onward (MECTA Corp, Tualatin, OR). The specialist used age-based dosing 19 to select intensity of ECT. Seizure duration was monitored by a single-channel EEG with the MECTA SR-1 and double-channel EEG with MECTA 5000-Q. Additional physiological monitoring included electrocardiography, automated blood pressure monitoring, and pulse oximetry.
The choice of electrode placement for ECT was at the discretion of the treating psychiatrist; however, bitemporal ECT . Three independent reviewers blind to patient identity extracted the data from the charts. One independent reviewer extracted demographic and psychiatric history data from the patient charts, using the checklist developed for this study. The other 2 independent reviewers rated the patients on the CGI-S and CGI-I scales, 20 the GAF scale, 21 and the SOFAS. 22 Conflicting scores were resolved by rater consensus.
The GAF scale, which constitutes Axis V of the DSM-IV classification system, is widely used as a brief measure of severity of psychiatric disturbance. Global psychological, social, and occupational functioning is rated from 1 to 100, with lower scores indicating worse function. The GAF score, however, can be difficult to interpret because it confounds severity of symptoms with difficulty in functioning, 23 so the SOFAS was used as another measure of psychosocial function. The SOFAS is a variation of the GAF in which only psychosocial functioning is rated.
Patients were assessed on the GAF and SOFAS prior to receiving ECT and were reevaluated on the same rating scales, in addition to the CGI-I, at the end of 6, 12, and 24 months. To be considered as having had a response to treatment, patients needed to have a rating on the CGI-I of either "much improved" or "very much improved." To be considered "much improved," the chart notes had to include indication of both subjective and objective improvement such that patients had unequivocal response, although some mild residual symptoms might have been still present. To be rated "very much improved," the notes had to indicate that patients were almost back to baseline function with minimal residual symptoms.
Statistical Analysis
Continuous data were analyzed with paired t tests or analysis of variance or repeated measures MANOVA, as appropriate. Categorical data were analyzed with chi-square or Fisher's exact tests, as appropriate. All data are presented as mean values and SDs. Statistical analyses were conducted with the R statistical software package, version 2.1.1. 24 The reported P values are 2-sided and statistical significance was assessed at a significance level a = 0.05.
Results
A total of 106 patients received ECT during the period covered by the chart review, with 100 having complete data. The patients' diagnoses were MDD (n = 68), BD (n = 22), and schizophrenia (n = 10). The remainder of the results and discussion will focus on the group of patients with mood disorders (MDD and BD), with special emphasis on the group of patients with MDD. Demographics, diagnoses, symptoms, and course of illness were gathered from the patients' charts ( Table 1 ). The long average duration of illness and treatment indicate that these patients were chronically and markedly ill at the time of receiving ECT.
Of the 90 patients with mood disorder diagnoses, 15 (12 patients with unipolar MDD and 3 patients with BD) were followed for 1 year and discharged from follow-up because they were doing well. The rest were followed for up to 2 years, although some patients were lost to follow-up, usually because they had improved or moved away. Follow-up data are presented for evaluable (observed case) patients at each time, although LOCF analysis was also done.
Clinical Response Following ECT: CGI Ratings
In the 90 patients with mood disorders, 86.5% had a baseline CGI-S rating within the categories of "markedly ill" to "among the most extremely ill"; however, by the end of 24 months, only 32.6% of patients met those severity criteria. Table 2 shows the CGI-I ratings. Patients with a good clinical response (much or very much improved on the CGI-I), represented 50.0%, 50.8%, and 56.7% of the evaluable patients at 6, 12, and 24 months post-ECT, respectively. The response rates from the LOCF data analysis are similar (50.0%, 46.2%, and 51.3% for 6, 12, and 24 months post-ECT, respectively), so subsequent results will present only the observed case data.
Psychosocial Outcomes: GAF and SOFAS Scores Pre-and Post-ECT Table 3 shows the GAF and SOFAS scores at baseline, 6, 12, and 24 months. Higher scores on the GAF and SOFAS indicate better psychosocial function. Overall, the mean GAF scores regardless of the Axis I diagnoses went from a low of 37, SD 9.3, at baseline to high of 58, SD 13.8, at 24 months, for a mean change of 21.2, SD 16.5 (t 43 = 8.4, P < 0.001). The mean SOFAS scores went from a low of 41, SD 9.6, at baseline to a high of 60, SD13.6, at 24 months, for a mean change of 18.8, SD 16.6 (t 41 = 7.3, P < 0.001). Similar results were seen with the LOCF data set (data not shown). A repeated measures MANOVA showed no significant differences between patients with MDD and BD in changes from baseline in GAF (F 3,33 = 0.71, P = 0.55) or SOFAS (F 3,27 = 0.18, P = 0.91) at any of the 3 follow-up times. No matter the diagnosis, patients continued to improve throughout the follow-up period.
On these rating scales, a change of 20 points or more represents substantial improvement in psychosocial functioning. This degree of improvement on the GAF and SOFAS was seen, respectively, in 41% and 34% of patients at 6 months, 50% and 44% at 1 year, and 53% and 55% at 2 years.
GAF and SOFAS Scores by Treatment Type: Subanalysis of Patients With MDD
A subanalysis of GAF and SOFAS scores by treatment type for patients with MDD (n = 68) was completed (Tables 4 and  5) . Of the 68 patients with MDD who received ECT, just over one-half (n = 32) required only an index course of treatment. The mean GAF score for these patients was 35.8, SD 7.8, at baseline, indicating poor function, improving to 59.6, SD 13.8, at 24 months. Similarly, the SOFAS scores for patients who required only an index course improved from a mean of 40.5, SD 8.8, at baseline to 61.1, SD 13.2, at 24 months.
The remaining patients, in addition to medication or other treatment changes, received additional ECT after the index course, such as maintenance ECT or a subsequent course of ECT, or both. These patients saw their GAF scores improve from a range of 37.7 to 41.3, SD 4.2 to 11.7, at baseline to 50.0 to 59. 
Discussion
This chart review study examined the clinical effects of ECT on psychosocial outcomes in a community setting. The strengths of the study include that it reports on a large number of consecutive, nonenriched patients treated at a single community hospital setting, with most of the ECT treatments being administered by a single psychiatrist. The limitations of this study, however, must also be noted. Because of the chart review methodology, the data are dependent on the quality of the chart information. Since the outcome assessments were based entirely on clinician notes, they may not accurately reflect subjective improvement and (or) the clinicians may be biased to report improvement. This limitation is mitigated in part because the notes were primarily written by a single specialist and, as such, were detailed and complete. Additionally, although DSM-IV criteria were used, diagnoses were made with clinical assessments instead of structured interviews. Therefore, these data may be less reliable than those obtained in prospective RCTs. However, our sample was community-based and is representative of the "real world," as opposed to tertiary care populations that are prone to selection bias in randomized studies (for example, because of strict inclusion and exclusion criteria). Finally, prior to ECT, the patients were taking different combinations of medications, and following ECT, the patients were treated in the community with usual care, including changes in medications; therefore, any effects found on longer-term outcomes may not be entirely attributable to the ECT alone.
Given these limitations, we describe the clinical responses and psychosocial outcomes of a large sample of community 17 The investigators noted that these represent lower response and remission rates than found in RCTs of ECT, owing in part to patient differences and also to treatment differences, notably the lower number of sessions of ECT provided in the community study.
Our results are comparable to those of Prudic and colleagues 17 at 6-month follow-up, as 41% of the original sample had clinical response by CGI-I criteria, although this represented over one-half of the observed case sample. Our study also extends the previous findings by assessing outcomes at 12 and 24 months, showing continued clinical response in 51% and 56%, respectively, of the evaluable patients (representing 37% and 25%, respectively, of the original sample).
These clinical response rates are based primarily on symptom measures. While symptom improvement is important, recovery can best be assessed by psychosocial and functional outcomes and QOL. Only one study reported on QOL following ECT. In a study of 283 patients receiving ECT at 7 hospitals in the New York City area, scores on the SF-36 (a standard measure of health-related QOL) improved significantly after ECT and at 6-month follow-up. 18 We found that patients significantly improved in scores on 2 similar measures of psychosocial functioning, the GAF and SOFAS, and that this improvement was maintained over the 24-month follow-up. These results were apparent in both the observed case and LOCF analyses. The magnitude of change in these scores (over 20 points on average) indicates clinically meaningful improvement in psychosocial functioning. There were no differences in response or psychosocial outcomes between patients with MDD and BD. It is possible that the relatively good psychosocial outcomes in this cohort of patients reflect the fact that many patients continued with maintenance ECT (29%) or received another course of ECT (26%) if a relapse occurred (in addition to possible changes in medications and use of other treatments). However, it should be noted that the average GAF and SOFAS scores in this population over the follow-up period were in the 54 to 62 range, which still indicates moderate difficulty in psychosocial functioning and that, at 2-year follow-up, 43% of patients were still rated as minimally improved or not changed. This likely reflects the fact that this patient cohort is characterized by having chronic and severe illnesses (as indicated by the average length of illness of 14.3 years) prior to treatment with ECT.
In summary, this study shows that patients with chronic mood disorders treated with ECT in a community setting show meaningful improvement in clinical response and psychosocial outcomes over a 24-month naturalistic follow-up period. This information will be informative for patients and clinicians as they weigh the short-and long-term risks and benefits of treatments for depression. 
